I hadn't looked at AGTC for a long time until just now. Stock is languishing below its EV and they have several data read-outs later this year on both the XLRP and achromatopsia programs. I know the company and stock have been a disaster to date but just wondering if any value here. NITE has at least had some PoC in XLRP and wondering if this could bode well for AGTC. I listened to their latest CC and they said what distinguishes their XLRP program from the XLRS that failed is that XLRP apparently has a good pre-clinical model where they have shown success vs. XLRS that had no good model. Also, they claim they are dosing sub-retinal with XLRP whereas XLRS indication was intravitreal (assuming that means chance for better delivery and, ultimately, efficacy).
Given the foregoing, you think they have a decent chance to show efficacy in the XLRP program?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.